About Cala health
Cala Health: Pioneering Neuroperipheral Therapy
Cala Health is a medical technology company that has been making waves in the healthcare industry with its innovative approach to treating chronic diseases. The company is at the forefront of a new class of electrical medicine called neuroperipheral therapy, which uses targeted electrical stimulation to activate specific nerves in the body and provide relief from symptoms.
Founded in 2014 by Kate Rosenbluth, PhD, Cala Health has quickly established itself as a leader in the field of neuromodulation. The company's flagship product, Cala Trio™, is an FDA-cleared wearable device that delivers personalized neuroperipheral therapy to patients with essential tremor (ET), a neurological disorder that causes involuntary shaking.
The Cala Trio™ device consists of three small electrodes that are placed on the wrist and deliver gentle electrical pulses to the median nerve. This nerve runs through the wrist and into the hand, where it controls movement and sensation. By stimulating this nerve with precise frequencies and intensities, Cala Trio™ can reduce tremors by up to 80% without any side effects.
But Cala Health's ambitions go beyond just treating ET. The company is exploring other applications for neuroperipheral therapy across a range of conditions such as migraine headaches, fibromyalgia, Parkinson's disease, and more.
One key advantage of neuroperipheral therapy over traditional drug-based treatments is its non-invasive nature. Unlike medications that can have serious side effects or require frequent dosing adjustments, neuroperipheral therapy does not involve any drugs entering your system or invasive procedures like surgery.
Another advantage is its precision targeting capabilities. With traditional drugs or even other forms of neuromodulation like deep brain stimulation (DBS), it can be difficult to achieve precise targeting without affecting surrounding tissues or causing unwanted side effects. Neuroperipheral therapy allows for highly targeted stimulation only where it's needed most.
Cala Health has also made significant strides in clinical research around neuroperipheral therapy. In addition to conducting multiple clinical trials for their own products like Cala Trio™ for ET treatment , they have also collaborated with leading academic institutions such as Stanford University School of Medicine on research projects related to neuromodulation therapies .
Overall ,Calas' mission statement revolves around improving patient outcomes through innovation . They believe that by harnessing cutting-edge technologies like neuroperipheral therapy , they can help millions suffering from chronic diseases lead better lives .
In conclusion,Cala health represents an exciting new frontier in medical technology . Their pioneering work on neuro-perpheral therapies could revolutionize how we treat chronic diseases going forward . With their focus on innovation , precision targeting capabilities ,and non-invasive nature ;they are well positioned for continued success in this rapidly evolving field .
calahealth.com
